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Abstract
Background: The aim of the study was to compare the effects of 2 strategies of antiplatelet 
treatment (i.e., 150 mg ASA vs. 75 mg clpoidogrel) on plasma level of inflammatory markers 
in type 2 diabetes mellitus (T2DM) patients with high platelet reactivity (HPR).
Methods: Study cohort consisted of 304 T2DM patients on chronic ASA therapy (75 mg per day) 
participating in the Aspirin Versus/Or Clopidogrel in Aspirin-resistant Diabetics inflamma-
tion Outcomes (AVOCADO) study. Patients with HPR defined as Platelet Function Analyzer 
(PFA)-100 collagene/epinephrine closure time (CEPI-CT) < 193 s (n = 80) were randomized 
to 150 mg of ASA or 75 mg of clopidogrel in 2:3 ratio, respectively. Concentrations of the selec-
ted inflammatory markers, including tumor necrosis factor (TNF)-a, interleukin (IL)-6, so-
luble CD40 ligand (sCD40L), and high sensitivity C-reactive protein (hsCRP), were measured 
and compared in both treatment groups before and after 8 weeks of treatment in both groups.
Results: Out of 234 patients included into final analysis, the total of 34.2% (n = 80) patients 
displayed HPR, of which 14.1% (n = 33) were randomized into 150 mg of ASA group and 
20.1% (n = 47) into 75 mg of clopidogrel group. Treatment with clopidogrel was a positive 
predictor (stepwise multiple regression analysis) of reduction of sCD40L concentration (odds 
ratio [OR] 4.15; p = 0.013), while treatment with 150 mg ASA was a positive predictor of 
reduction of IL-6 concentration (OR 4.38; p = 0.033). There was no statistically significant 
differences between clopidogrel and ASA 150 mg treatment in respect to predictive value for 
decreased hsCRP concentrations or increased TNF-a concentrations.
Conclusions: Increasing the dose of ASA from 75 mg to 150 mg daily or switching ASA 75 mg 
to clopidogrel 75 mg daily may reduce concentrations of some inflammatory markers (in parti-
cular hsCRP, IL-6 and CD40L) in T2DM patients with HPR treated previously with 75 mg of 
ASA. (Cardiol J 2013; 20, 5: 545–551)
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Introduction
Patients with type 2 diabetes (T2DM) have 
a 2- to 4-fold higher risk for cardiovascular (CV) 
disease as compared with non-diabetic individuals 
[1]. It is caused partly by hypercoagulable state 
as evidenced by high platelet reactivity (HPR) 
[2]. Etiology of HPR is complex, and seems to be 
a result of hyperglycemia, metabolic disorders, 
oxidative stress and inflammation [3]. In particu-
lar, T2DM patients have higher concentrations 
of inflammatory markers, platelet activation and 
coagulation markers than healthy subjects [4–6]. 
Moreover, higher concentrations of inflammatory 
markers correlate with increased CV risk [7, 8]. 
There have been very few studies that evaluated 
the anti-inflammatory effects of antiplatelet the-
rapy in T2DM patients [9, 10]. According to the 
American Diabetes Association guidelines, high-
-risk T2DM patients should be treated with low 
doses of acetylsalicylic acid (ASA) in primary or 
secondary prevention of myocardial infarction (MI) 
[11]. However, some of T2DM patients experience 
CV events despite treatment with ASA and that 
might be, at least in part, related to HPR, despite 
treatment with low-doses of ASA [12, 13]. 
In spite of recent advances in antiplatelet 
therapy the optimal treatment strategy is yet to be 
established in patients with HPR despite treatment 
with low dose of ASA (i.e. 75 mg per day). Previous 
studies demonstrated that T2DM patients treated 
with 162 mg ASA had lower incidence of HPR 
than those receiving 81 mg, however increasing 
the dose to 325 mg had not resulted in further im-
provement in terms of platelet reactivity [14, 15]. 
Also in the AVOCADO study switching to higher 
dose of ASA reduced platelet reactivity in T2DM 
patients with HPR initially treated with 75 mg of 
ASA per day [16]. 
It was hypothesized that dose-related inhibi-
tion of platelet aggregation may be due to effects 
of ASA beyond inhibition of its primary target 
cyclooxygenase (COX-1) by acetylation and was 
termed a non-COX-1 effect [15]. Thus, in our study 
shear dependent platelet functions were measured 
with less COX-1 inhibition dependent device — 
Platelet Function Analyzer (PFA)-100.
The aim of our prospective and randomized 
study was to compare the effects of 2 strategies 
of antiplatelet treatment (150 mg ASA vs. 75 mg 
clopidogrel) on the plasma level of selected inflam-
matory mediators (hsCRP, IL-6, TNF-a, sCD40L) 
in T2DM patients with established HPR, (diagno-
sed with PFA-100 collagen/epinephrine closure 
time (CEPI-CT) assay during previous treatment 
with 75 mg of ASA).
Methods
The study subjects were recruited conse-
cutively from patients with T2DM (participating 
in a multi-center, prospective, randomized, and 
open-label Aspirin Versus/Or Clopidogrel in Aspi-
rin-resistant Diabetics inflammation Outcomes 
(AVOCADO) study presenting to the outpatient 
clinic of the Central Teaching Hospital of the Medi-
cal University of Warsaw. The full characterization 
of the study population, including the inclusion and 
exclusion criteria were published previously [17]. 
Briefly, the Caucasian subjects with T2DM were 
recruited who, at the time of enrollment, had been 
taking ASA tablets at the dose of 75 mg per day for 
at least 3 months for primary or secondary preven-
tion of myocardial infarction (MI). No clopidogrel or 
antiplatelet drugs other than ASA were used in any 
of the investigated patients. All patients had been 
taking oral antidiabetic agents and/or insulin for 
at least 6 months; diet-controlled diabetic patients 
were not included. Compliance to ASA therapy at 
the study entry was determined based upon the 
patient’s own statement and serum thromboxane 
B2 (sTXB2) level measurement. 
Blood sample and assay procedures
Blood samples were taken in the morning 2–3 h 
after the last ASA dose. Regular laboratory testing 
was performed using standard laboratory techniqu-
es. The concentration of functional epitope of the 
von Willebrand factor (vWF) molecule (vWF:Ag) was 
measured in citrate plasma samples using an enzyme 
immunoassay kit according to the manufacturer’s 
instructions (vWF Activity Kit, American Diagno-
stica Inc., USA). Serum TXB2 concentrations were 
measured also with an enzyme immunoassay (EIA) 
kit according to the manufacturer’s instructions 
(EIA kits, Cayman Chemicals, Ann Arbor, MI, USA). 
Each lot of TXB2 EIA kit was tested for the impact 
of interferences. The correlation of results in three 
dilutions of 5 random samples was assessed, as was 
proposed in kit protocol. The decision to use the 
assay without purification was taken after analysis 
of results, as differences of results did not exceed 
20%. Samples with results outside the standard 
curve were re-assayed with appropriate dilutions. 
The compliance with ASA treatment was defined by 
the sTXB2 levels below 7.2 ng/mL [13].
ELISAs were used to determine concentra-
tions of tumor necrosis factor (TNF)-a (Quanti-
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kine® HS ELISA Human TNF-a Immunoassay), 
interleukin (IL)-6 (Quantikine® HS ELISA Human 
IL-6 Immunoassay; both R&D Systems, Inc., 
Minneapolis, USA) and soluble CD40 ligand 
(sCD40L; Human soluble CD40 Ligand Immu-
noassay, R&D Systems, Inc., NE, USA), and high 
sensitivity C-reactive protein (hsCRP) concen-
trations were assessed using Cobas Integra 800 
(Roche, Basel, Switzerland). 
Analysis of platelet functions
Platelet reactivity was measured with PFA-100 
assay (Dade-Behring International, Inc., Newark, 
DE, USA). These assays were performed as de-
scribed in detail previously [13]. In current study, 
normal platelet reactivity on ASA therapy with 
a PFA-100 was defined as CEPI-CT ≥ 193 s (the 
manufacturer’s lower limit of the normal range for 
aspirin-free healthy controls). Patients with HPR 
defined as CEPI-CT < 193 s were randomized to 
double dose (150 mg) of ASA or 75 mg of clopi-
dogrel in 2:3 ratio, respectively. After 8 weeks of 
follow-up period inflammatory markers concentra-
tions were re-assayed.
Statistical analysis
Normally distributed continuous variables 
were presented as means ± SD, whereas variables 
with a highly skewed distribution were presented as 
medians (interquartile ranges). Categorical variab-
les were presented as frequencies (percentages). 
Normality of distribution was assessed using grap-
hical methods. Differences between groups were 
analyzed using Student’s t-test, the Mann-Whitney 
U-test, the c2 or Cochran-Mantel-Haenszel test, as 
appropriate. Selected variables were checked for 
associations with changes in inflammatory markers 
concentrations using a univariate and multivariate 
stepwise logistic regression models. The results 
were presented as odds ratios (OR) with their 95% 
confidence intervals (CI). A 2-sided p-value of 
< 0.05 was considered significant.
Power analysis
We were planning a prospective study of 
2 independent experimental groups (clopidogrel 
75 mg vs. ASA 150 mg), with 3 patients treated with 
clopidogrel 75 mg treated patients per 2 patients 
treated with ASA 150 mg (ratio 3:2). Prior data 
indicate that the response rate (defined as percen-
tage of patients in the groups with decreased or 
increased of any measured inflammatory marker) 
among clopidogrel treated patients was 0.5. If the 
true response rate for ASA-treated subjects differs 
by 0.35, we will need to study at least 28 ASA 
150 mg treated patients and at least 39 clopidogrel 
75 mg treated subjects (total number of subjects 
at least 77) to be able to reject the null hypothesis 
that the response rates for subjects in both treated 
group are equal with probability (power) 0.8. The 
Type I error probability associated with this test 
of this null hypothesis is 0.05. We used an Fisher’s 
exact test to evaluate this null hypothesis.
Results
From the initially enrolled 304 patients, com-
plete clinical data and blood samples finally became 
available for 260 patients. Subsequently, 8 patients 
were eliminated from the analysis based on sus-
pected ASA non-compliance (sTXB2 concentrations 
> 7.2 ng/mL). Baseline characteristics are pre-
sented in Table 1. Twenty patients were excluded 
from the analysis due to elevated concentrations 
of hsCRP (> 10 mg/L) indicating potential subcli-
nical infection. Out of 234 patients included into 
final analysis 34.2% (n = 80) patients had HPR of 
which 14.1% (n = 33) were randomized to 150 mg 
of ASA group and 20.1% (n = 47) to 75 mg of 
clopidogrel group. 
After 8 weeks of treatment with either me-
dication we observed a significant reduction of 
hsCRP: D (change in concentrations of marker after 
8 weeks of follow-up) = –0.4 (–1.3 – 0.2); p = 0.006 
and IL-6: D = –0.714 (–1.435 – 0.150); p < 0.001, 
as well an increase of TNF-a: D = 0.552 (0.064 
– 0.931); p < 0.001 in group receiving 150 mg of 
ASA. We also observed a significant reduction of 
hsCRP: D = –0.3 (–1.0 – 0.1); p = 0.008, no change 
for Il-6: D = 0.045 (–1.247 – 0.779); p = 0,587 and 
an increase of TNF-a: D = 0.778 (0.129 – 1.670); 
p < 0.001 in group receiving clopidogrel. The calcu-
lated response rate for hsCRP and TNF-a in both 
experimental groups was similar and did not differ 
significantly (p > 0.05) between 150 mg ASA and 
75 mg clopidogrel group by the Fisher’s exact test 
analysis. In a Mann-Whitney test analysis we found 
a significant difference in the magnitude of change 
for IL-6 concentrations between groups (–0.714 
in 150 mg of ASA group vs. 0.024 in clopidogrel 
group; p = 0.034). There was also significantly 
higher percentage of patients with IL-6 reduction 
in group receiving 150 mg of ASA than in group re-
ceiving clopidogrel (72.7% vs. 48.9%, respectively; 
p = 0.033 by Fisher’s exact test). 
There was no difference in the change of con-
centrations of sCD40L between studied groups, 
but there was a significantly higher percentage 
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of patients in clopidogrel group with sCD40L re-
duction than in group taking 150 mg of ASA (61.7% 
vs. 33.3%, respectively; p = 0.012, by Fisher’s 
exact test). 
In stepwise multiple logistic regression analysis 
adjusted to age and gender, treatment with 150 mg 
ASA (OR 4.38; 95% CI 1.13 – 17.02; p = 0.033) 
and higher white blood count (WBC) (for each 2 × 
× 103/mm3: OR 7.43; 95% CI 2.51 – 21.97; p < 0.001) 
were positive predictors of reduction of IL-6 con-
centration, while higher glycosylated hemoglobin 
(HbA1c) (for each 1%: OR 0.56; 95% CI 0.34 – 0.91; 
p = 0.02) and body mass index (BMI) (for each 
5 kg/m2: OR 0.15; 95% CI 0.05 – 0.50; p = 0.002) 
and history of MI (OR 0.21; 95% CI 0.05 – 0.88; 
p = 0.033) were negative predictors of reduction 
of IL-6 concentration (Fig. 1). Patients treated 
with statins had higher chance of reduction of 
hsCRP concentration (OR 3.72; 95% CI 1.05 – 13.2; 
p = 0.042), while patients with history of MI had 
lower chance of reduction of this parameter (OR 
0.25; 95% CI 0.08 – 0.81; p = 0.021). Only higher 
HbA1c was a negative predictor of reduction of 
TNF-a concentration (OR for reduction of TNF-a: 
0.287; 95% CI 0.09 – 0.87; p = 0.027). There was 
no difference in change of hsCRP and TNF-a con-
centrations between studied groups. 
Treatment with clopidogrel was a positive 
predictor of reduction of sCD40L concentration 
Table 1. Demographic and clinical characteristics 
of the study patients (n = 254).
Demographics
Male 136 (53.5%)
Age [years] 67.1 ± 8.5
SBP [mm Hg] 141.3 ± 19.3
DBP [mm Hg] 79.8 ± 11.6
BMI [kg/m2] 30.7 ± 4.9
WHR 0.96 ± 0.08
Comorbidities
Hypertension 235 (92.5%)
Coronary artery disease 137 (53.9%)
Prior MI 77 (30.3%)
Dyslipidemia 214 (84.3%)
Chronic heart failure 94 (37.2%)
Prior stroke and/or TIA 28 (11.0%)
History of smoking 149 (58.7%)
Current smoking 26 (10.2%)
Concurrent medications
Metformin 162 (63.8%)
Insulin 83 (32.7%)
Beta-blockers 183 (72.0%)
ACE inhibitors 168 (66.1%)
Statins 184 (72.4%)
Proton pump inhibitors 31 (12.2%)
Biochemical parameters
WBC [103/µL] 7.1 ± 2.0
HGB [g/dL] 13.9 ± 1.3
HTC [%] 41.6 ± 3.7
PLT [103/µL] 228.8 ± 61.3
MPV [fl] 9.9 ± 1.2
eGFR (MDRD) [mLmin/ 
/1.73 m2]
70.9 ± 20.4
HbA1c [%] 7.0 ± 1.3
Total cholesterol [mg/dL] 164.9 ± 40.0
HDL [mg/dL] 48.7 ± 13.9
LDL [mg/dL] 88.9 ± 33.5
Triglycerides [mg/dL] 136.7 ± 68.3
vWF [%] 144.7 ± 57.4
CEPI-CT [s] 257 (172–300)
sTXB2 [pg/mL] 153.2 (45.7–546.3)
Inflammatory markers (n = 234)*
hsCRP [mg/L] 2.3 (1.4–4.0)
sCD40L [ng/mL] 0.582 (0.349–0.909)
TNF-a [pg/mL] 1.753 (1.244–2.292)
IL-6 [pg/mL] 2.193 (1.504–3.672)
*Inflammatory markers concentrations after excluding patients 
with hsCRP > 10 mg/L; SBP — systolic blood pressure;  
DBP — diastolic blood pressure; BMI — body mass index;  
WHR — waist-to-hip ratio; MI — myocardial infarction;  
TIA — transient ischemic attack; ACE — angiotensin converting 
enzyme; WBC — white blood cells count; HGB — hemoglobin; 
HTC — hematocrit; PLT — platelet count; MPV — mean platelet 
volume; eGFR — estimated glomerular filtration rate;  
HbA1c — glycosylated hemoglobin; HDL — high density lipo-
proteins; LDL — low density lipoproteins; vWF — von Wille-
brand factor; CEPI-CT — collagen/epinephrine closure time; 
sTXB2 — serum thromboxane B2 concentration; hsCRP — high-
-sensitivity C-reactive protein; sCD40L — soluble CD40 ligand; 
TNF-a — tumor necrosis factor-alpha; IL-6 — interleukin-6
1/32 1/16 1/8 1/4 1/2 1 2
OR (95% CI)
4 8 16 32
[ASA 150
vs. clopid]
WBC
[2 ×
10 /mm ]3 3
BMI
[5 kg/m ]2
HbA1c
[1%]
sTXB
[100
pg/mL]
2
Prior MI
Figure 1. Factors influencing reduction of interleukin-6 
(IL-6) concentrations in multivariate analysis; ASA 150 
— patients randomized to receiving 150 mg of acetylsa-
licylic acid; clopid — patients randomized to receiving 
75 mg of clopidogrel; WBC — white blood cells count; 
BMI — body mass index; HbA1c — glycosylated he-
moglobin; sTXB2 — serum thromboxane-B2; MI — myo-
cardial infarction; OR — odds ratio; CI — confidence 
interval.
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(OR 4.15; 95% CI 1.34 – 12.82; p = 0.013) while 
current smoking (OR 0.93; 95% CI 0.87 – 0.99; 
p = 0.028) and higher sTXB2 concentrations 
(OR 0.93; 0.87 – 0.99; p = 0.024) were negative 
predictors of reduction of this parameter (Fig. 2). 
Discussion
The present study demonstrate that treatment 
with either 150 mg of ASA or 75 mg of clopidogrel 
result in significant reduction of hsCRP, sCD40L, 
IL-6 (only in and ASA treated patients) and in 
increase of TNF-a inflammatory markers concen-
tration in T2DM patients with stable coronary 
artery disease (CAD) or multiple risk factors for 
CAD. No statistically significant differences were 
observed between the treatment groups in respect 
to the magnitude of changes (defined as the fraction 
of patients treated with ASA or clopidogrel with 
decreased concentrations of hsCRP or increased 
concentration of TNF-a). Treatment with ASA vs. 
clopidogrel caused however different effect on 
response rate related to Il-6 and sCD40L inflam-
matory markers (i.e., significant increase in the 
response rate for decreased IL-6 in only ASA 150 mg 
group, and significant increase in the response 
for decreased sCD40L only in clopdogrel group). 
Moreover, the results of this study show that both 
antiplatelet therapies were less effective in terms 
of their anti-inflammatory activity in patients with 
higher BMI, currently smoking and with a history 
of MI. 
Several previous studies demonstrated anti-
-inflammatory effect of low doses of ASA and 
clopidogrel, mainly in patients with CAD [18–25]. 
The results of subanalysis of Physician’s Health 
Study suggested that cardioprotective effect of ASA 
correlated with its anti-inflammatory effect [26]. 
There are very few studies assessing the effect 
of different doses of ASA on inflammatory state 
in patients with T2DM. Hovens et al. [9] demon-
strated that there was no difference in hsCRP and 
IL-6 concentrations in patients with T2DM treated 
with either 100 mg or 300 mg of ASA, or placebo. 
In our study doubling the dose of ASA in pa-
tients with HPR resulted in a significant reduction 
of hsCRP and IL-6 concentrations with more than 
4-fold higher chance of IL-6 reduction than in 
a group treated with clopidogrel. Herder et al. [27] 
observed that high IL-6 levels in patients with 
diabetes were associated with increased risk for 
primary CV events (MI, stroke and CV death). 
Thus, doubling the dose of ASA by reducing IL-6 
and hsCRP concentrations could be more effective 
in reducing the CV risk of patients with diabetes 
and HPR during treatment with 75 mg of ASA, 
but this hypothesis should be confirmed in further 
larger studies with well defined clinical end-points. 
In the Diabetes Heart Study higher hsCRP 
concentration was a predictor of mortality in pa-
tients with T2DM [28]. In our study both antipla-
telet treatment strategies resulted in significant 
reduction in hsCRP concentrations. In multivariate 
analysis the history of MI was a negative predictor 
of reduction of hsCRP concentrations (OR 0.25; 
95% CI 0.08 – 0.80; p = 0.021). According to the 
results of recent meta-analysis, treatment with 
ASA in primary prevention of CV diseases rema-
ins of uncertain value in diabetic population [29]. 
Patients with a history of MI tend to have higher 
concentrations of hsCRP and treatment with ASA 
results in more reduction of MI risk in patients with 
higher levels of hsCRP than in patients with lower 
concentrations of hsCPR [26, 30, 31]. However, in 
our study patients with T2DM and with a history 
of MI which were chronically treated with 75 mg of 
ASA had lower baseline hsCRP concentrations than 
patients treated with ASA in primary prevention 
of MI, although due to small number of subjects 
the difference was not statistically significant. 
Moreover, treatment with higher dose of ASA 
or switching from ASA to clopidogrel resulted 
in additional reduction of hsCRP concentrations 
especially in patients without history of MI. This 
may indicate that patients treated with 75 mg of 
ASA in primary prevention of MI might require 
Figure 2. Factors influencing reduction of soluble CD40 
ligand (sCD40L) concentrations in multivariate analysis; 
ASA 150 — patients randomized to receiving 150 mg 
of acetylsalicylic acid; clopid — patients randomized to 
receiving 75 mg of clopidogrel; sTXB2 — serum throm-
boxane-B2; OR — odds ratio; CI — confidence interval.
1/32 1/16 1/8 1/4 1/2 1 2
OR (95% CI)
4 8 16
[ASA 150
vs. clopid]
Current
smoking
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modification of antiplatelet therapy, higher doses 
of ASA or switching to clopidogrel, which may cau-
se additional benefit in terms of reducing hsCRP 
levels in this subgroup of patients.
In our study the median of sCD40L concentra-
tions after 8 weeks of treatment with clopidogrel 
increased, but we observed a decrease in sCD40L 
concentrations in almost twice as many patients in 
this group as in group treated with 150 mg of ASA. 
There was also more than 4-fold higher chance 
of reduction in sCD40L concentration in patients 
treated with clopidogrel than in patients treated 
with 150 mg of ASA. Several studies have indicated 
that levels of circulating sCD40L are significantly 
higher in patients with acute MI or unstable angina 
and that sCD40L may be the marker of high risk 
population among patients with acute coronary 
syndrome [32, 33]. Therefore, it was suggested 
that sCD40L may be a therapeutic target and the 
reduction of its concentrations may lead to impro-
ved clinical outcome [34]. Our study is the first 
showing that clopidogrel is much more effective 
than ASA in reducing sCD40L concentrations in 
diabetic population, but it seems to be less effective 
in smokers than in non-smoking population. These 
results may indicate, that switching to clopidogrel, 
along with smoking cessation, could be an optimal 
therapy in patients with T2DM and HPR during 
treatment with 75 mg of ASA in terms of reduction 
of inflammatory markers concentrations. 
Limitations of the study
The inherent limitations of open-label design 
apply to this study. Another limitation is related to 
the choice of the test for measurement of platelet 
reactivity for diagnosis of HPR. Light transmis-
sion aggregometry (LTA) is considered to be the 
gold standard platelet function test but is poorly 
standardized, requires a specialist laboratory and 
is unlikely to be used widely in routine clinical 
practice [35]. Moreover LTA measures more 
specifically effects of COX-1 dependent pathway 
of platelet activation, while PFA-100 by using 
different platelet agonists, measures more global 
platelet reactivity [36]. 
Conclusions
Increasing the dose of ASA from 75 mg to 
150 mg daily or switching ASA 75 mg to clopido-
grel 75 mg daily reduce concentrations of hsCRP, 
IL-6 and sCD40L inflammatory markers in T2DM 
patients with HPR and treated previously with 
75 mg of ASA. Doubling the dose of ASA was more 
successful in reducing IL-6, while clopidogrel was 
better in reducing sCD40L. Anti-inflammatory ef-
fects of these 2 strategies were smaller in currently 
smoking patients with a history of MI, poorer long-
-term glycemic control and higher BMI.
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